PLATFORM
Blood-based profiling of the tumor microenvironment.
Clyra combines complementary molecular layers from routine blood draws into a repeatable view of tumor microenvironment composition and activity during treatment.
REPEATABLE TME PROFILING
01
At baseline
02
During treatment
One tissue snapshot is not enough.
Immunotherapies and other TME-dependent drugs are often selected and evaluated on a single biopsy taken before treatment. The tumor microenvironment changes over time and under therapy, and repeat biopsies are invasive and rarely feasible. Development teams are left making decisions on a static, partial view.
A static view of a changing system
PLATFORM
One blood draw. A view of the tumor microenvironment.
01
Routine blood draw
A standard blood sample, collected at any visit.
02
Complementary molecular layers
Multiple molecular layers capture both the cellular composition of the tumor microenvironment and what those cells are doing.
03
Integrated TME state
The layers are combined into a single TME readout that no single layer provides alone, and it can be repeated at every visit.
WHY CLYRA
What makes Clyra different.
Composition and activity
We read which cells are present and what they are doing, not just one or the other.
Longitudinal by design
Blood-based, so the tumor microenvironment can be measured repeatedly over the course of treatment.
Built with drug developers
Deliverables designed around trial decisions: patient selection, biomarker strategy, and next-phase design.